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Lung cancer is the leading cause of death in the United States and Japan (1, 2). The current prognosis for patients with advanced lung cancer is unsatisfactory even with chemoradiotherapy. Several molecular-targeted agents have been used in the clinical setting and have yielded improved prognoses for advanced lung cancer, especially in patients with somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene by EGFRtyrosine kinase inhibitors (3, 4).
EGFR mutation is frequently observed in patients who are East Asian, female, non-smokers, and diagnosed with adenocarcinoma (5, 6). Regarding smoking status, Pham et al. reported that smoking history may be a predictor of lowfrequency EGFR mutation (7). Jida et al. also reported that the cumulative smoking dose and frequency of EGFR mutation status are negatively correlated in Japanese patients with non-small-cell lung carcinoma (8) . Therefore, EGFR mutation is regarded as an oncogenic driver mutation of lung cancer in non-smokers and light smokers (9, 10) . The frequency of EGFR mutations in patients with lung cancer who are non-smokers or light smokers was reported to be 11-43.5% (8, (10) (11) (12) . However, the reason for the low frequency in patients with lung cancer who smoke remains unclear.
Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation and chronic inflammatory reactions in the airways and lung in response to noxious particles or gases. Cigarette smoking is the major risk factor for the development and progression of COPD (13) (14) (15) . Cigarette smoke contains toxic chemicals and causes inflammation in the lung. The characteristic chronic airflow limitation observed in COPD is caused by a mixture of diseases of the small airways (obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary among individuals (16) . COPD is commonly observed in patients with lung cancer who are habitual cigarette smokers (17) . Regardless of cumulative smoking dose, patients with chronic airflow obstruction have a greater risk for lung cancer (18, 19) . In recent studies addressing the association between emphysema and lung cancer, the presence of emphysema detected using chest computed tomography (CT) in smokers is reported to be an important risk factor for lung cancer and poor prognosis (20) (21) (22) (23) (24) (25) . Thus, we hypothesized that genetic abnormality, including driver mutations, in lung cancer may differ according to the presence or absence of emphysema even in patients with the same histological type of cancer. In the present study, we evaluated the association between emphysematous changes in the lung parenchyma and EGFR mutation status in patients with lung adenocarcinoma with a history of cigarette smoking.
Patients and Methods
Patients and data collection. The medical records of 250 patients who visited Tottori University Hospital from April 2008 to September 2011 and were diagnosed with lung adenocarcinoma were retrospectively studied.
The EGFR mutation status was studied using clinically obtained samples from transbronchial lung biopsy, pleural effusion, or surgically resected tumors. This study protocol was reviewed and approved by the Ethics Committee of Tottori University. (#1054) The medical records were reviewed to obtain clinical and demographic data, including sex, age, smoking history, histological results, clinical stage, treatment, and survival.
Measurement of pulmonary function. Pulmonary function tests were performed in all study patients using a flow spirometer (Chestac 33 spirometer: Chest Co., Tokyo, Japan) according to the standards of the American Thoracic Society (26) . Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured. %FVC is the FVC expressed as a percentage of the predicted value for sex and height using reference equations from Baldwin et al. (27) . %FEV1 is the FEV1 expressed as a percentage of the predicted value (28) .
EGFR mutation analysis. The presence of EGFR mutations was determined with the peptide nucleic acid-locked nucleic acid PCRInvader method (BML Inc., Tokyo, Japan).
CT imaging protocol. Chest CT scans were performed using a helical CT scanner (Aquilion 64;Toshiba, Tokyo, Japan) while the participants held their breath at full inspiration. The scanning parameters were as follows: tube current, 40 mA and scan time of 1 second per gantry rotation, 120 kVp. Axial images were reconstructed with a high spatial frequency (lung) algorithm at contiguous, 2-mm, non-overlapping intervals. CT images were viewed on a Monochrome LCD (ME355i2) monitor display system (TOTOKU, Tokyo, Japan) using standard lung window settings.
Assessment of pulmonary emphysema. The severity and distribution of pulmonary emphysema were determined from high-resolution CT scans. All images were interpreted by two expert chest radiologists to assess for the presence of emphysema using validated criteria (29) . In brief, the extent of emphysema was graded from 0 to 4, with a grade of 0 indicating no emphysema and a grade of 4 indicating the presence of emphysema in more than 75% of the lung. In this study, patients with grade 1 or more were classified as having emphysema and those with grade 0 as having no emphysema.
Statistical analysis. Differences among the categorized groups were compared using the two-sided Fisher's exact test, Mann-Whitney test, or chi-square test. Multivariate logistic regression analysis was used to check for independence to evaluate factors associated with EGFR mutations. Data were analyzed using PASW statistics 18 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6 (GraphPad Software Inc., San Diego, CA, USA) software.
Results
Patient characteristics are shown in Table I . In this study, the majority of the patients were male (91%). The median cumulative smoking dose was 46 pack-years. On the basis of the CT findings, we divided the patients into two groups: the non-emphysema group and emphysema group. Herein, 163 patients (65%) were categorized into the nonemphysema group and 87 patients (35%) into the emphysema group. In this study, we surveyed the EGFR mutation status in the patients with lung cancer, but were ANTICANCER RESEARCH 37: 765-772 (2017) 766 unable to obtain the data for 66 (26%) patients owing to lack of or poor preservation of the samples (Table I) .
We next compared the characteristic features of patients with lung cancer between the non-emphysema and emphysema groups (Table II) . The cumulative smoking dose as pack-years was significantly higher (p=0.012), and FEV1 (% predicted value) and FEV1/FVC significantly lower (p=0.0014 and p=0.0029, respectively) in the emphysema group. Interestingly, the percentage of EGFR mutation was significantly higher in the non-emphysema group (25%; p=0.0014). Furthermore, the frequency of EGFR mutation was higher in the non-emphysematous group (p=0.0008). The percentage of EGFR mutation was 34% in the nonemphysema group and 12% in the emphysema group.
We next compared pulmonary function between patients with wild-type EGFR and those with mutant EGFR in the non-emphysema group. Although neither the FVC nor FEV1 differed, FEV1/FVC in patients with mutant EGFR was significantly higher than in patients with wild-type EGFR (p=0.047; Table III ). Despite the limited comparison within the non-emphysema group, there was a functional difference between the wild-type and mutant groups. We also compared pulmonary function between patients with wild-type EGFR and mutant EGFR in the emphysema group but found no significant difference (data not shown).
Since the status of EGFR mutation is similar in light smokers and non-smokers, we excluded the data for light smokers (<10 pack-years) and examined the clinical characteristics of patients with lung cancer who smoked more than 10 pack-years (Table IV) . The clinical parameters were compared between the wild-type and mutant EGFR groups. The cumulative smoking dose was higher (56 vs. 40 pack-years; p=0.0003) and FEV1/FVC was lower (69% vs. 73%; p=0.021) in the wild-type EGFR group than in the mutant EGFR group. In addition, the rate of emphysema was higher in the wild-type EGFR group than in the mutant EGFR group (45% vs. 17%, p=0.0008).
Finally, we conducted a multivariate logistic regression analysis to identify which factors affect the EGFR mutation status. We set EGFR mutation as a dependent variable and factors that demonstrated statistical differences between the presence and absence of EGFR mutation as independent variables. As shown in Table V 
Discussion
In this study, we showed that the frequency of EGFR mutation was higher in the non-emphysema group than in the emphysema group. Furthermore, we found that the patients with EGFR mutation had better respiratory function, and the absence of emphysema was independently associated with EGFR mutation-positive status in heavy smokers. Indeed, smoking is one of the most important risk factors for lung cancer (30) . However, lung cancer does occur in never-smokers: 10-32.8% of patients with lung cancer have never smoked (31) (32) (33) (34) . Several factors, such as environmental tobacco smoke, residential radon, cooking oil vapors, indoor coal and wood burning, viral factors, and genetic factors have been identified as risk factors for lung cancer (33) . Recently, lung cancer in never-smokers has been recognized as a separate entity and is classified into non-smoking-associated and smoking-associated lung cancer (33, 34) . Although the etiology of non-smokingassociated lung cancer remains to be clarified, smokers are estimated to be exposed to the same lung cancer-related risk factors as never-smokers. In heavy smokers, the causes of the lung carcinogenesis are not completely attributable to smoking. Therefore, carcinogenesis related to nonsmoking-associated lung cancer occurs in current and former smokers (35) .
Some genetic alterations including p53 point-mutation and KRAS proto-oncogene, GTPase (KRAS) mutation are strongly associated with cigarette smoking in patients with lung cancer (36) (37) (38) . On the other hand, EGFR mutations and the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase fusion gene (EML-ALK) are likely to occur in never-smokers (8, (39) (40) (41) . Moreover, smoking itself may not cause EGFR mutation (11) . Thus, EGFR mutation can be regarded as a marker of nonsmoking-associated lung cancer. Since the frequency of EGFR mutations was significantly different between patients with and those without emphysema (Table II) , we speculate that the impact of smoking was considerably different between the these two groups in terms of carcinogenesis. The reason why the frequency of EGFR mutations seemed to be low in smokers is that lung cancer in smokers is more likely to include other molecular alterations such as KRAS mutation, serine/threonine kinase 11 (LKB1) alteration, or DNA methylation (42, 43) .
In this study, we compared the clinical characteristics of patients with lung cancer, except for those who were light smokers, and found the proportion of those with EGFRmutant status to be significantly higher in the nonemphysema group. The pathophysiology of emphysema can be characterized by the imbalance between proteinases and their inhibitors, increased apoptosis of lung epithelial and endothelial cells, excessive oxidative burden, and inflammatory cell infiltration (44) . With respect to the development of emphysema, the impact from smoking varies individually. The reason why all smokers do not develop emphysematous changes has not yet been determined. Betsuyaku et al. showed that neutrophil elastase in alveolar macrophages is related to emphysematous changes in current smokers (45) . Although susceptibility factors for the development of emphysematous changes have been studied in genome-wide association studies (46) , those associated with emphysema largely depend on host genetics; moreover, susceptibility in terms of not developing emphysema might also depend on host genetics. Some genetic factors related to non-emphysematous changes might be related to carcinogenesis and EGFR mutation status.
In this study, although the smoking dose was higher in the emphysema group than in the non-emphysema group, the difference was less than 6 pack-years, and both groups had smoking doses adequate to cause long-term lung inflammation (Table II) . Clinically, even in the non-emphysema group, the smoking dose was sufficient to induce pulmonary emphysema. Nevertheless, the non-emphysema group did not develop CTdetectable emphysema, suggesting that the emphysemainducing mechanism caused by smoking was resolved in the non-emphysema group. Thus, the non-emphysema group is regarded to have undefined defensive mechanisms against harmful reactions evoked by smoking. However, the aforementioned mechanisms leading to emphysema can be causes for carcinogenesis or promote tumor growth (47) . Given that smoking-induced carcinogenesis depends, at least partially, on emphysema-developing mechanisms, the carcinogenesis risk from smoking should have been relatively low in the non-emphysema group in this study because this group is estimated to be relieved of the emphysema-inducing mechanism caused by smoking. Consequently, a relatively high proportion of cases in the non-emphysema group may be non-smoking-associated lung cancer, and a large proportion in the emphysema group may be smoking-associated. These speculations are supported by another finding. In the non-emphysema group, patients with EGFR mutation had higher FEV1/FVC values than those with wild-type EGFR. This difference is attributable to better airway patency in those with mutant EGFR, even in the non-emphysema group. Mutant EGFR lung cancer represents non-smokingassociated lung cancer, and in such patients, smoking may be less carcinogenic to airway parenchyma.
There are many reports about the frequency of EGFR mutation. Smoking history has predictive value for the absence of EGFR mutation, and the frequency of EGFR mutations is inversely associated with cumulative smoking dose (12, 39) . Our results also showed a similar tendency (Table IV) . Interestingly, multivariate analysis showed that both cumulative smoking dose and the absence of emphysema but not FEV1/FVC were independently negatively associated with the frequency of EGFR mutation (Table V) . Therefore, we speculate that even in smokers with adenocarcinoma, the presence or absence of CT-detected emphysema has significant value in terms of estimating oncogenic mechanisms and genetic abnormalities, and the absence of emphysema has a predictive value for EGFR mutation.
Clinical implications. We propose that the present results may be valuable in clinical practice. Identification of driver mutations is important to guide treatment strategies for nonsmall-cell lung carcinoma. Since KRAS and EGFR mutations are mutually exclusive as driver mutations (24, 48, 49) , in theory, the frequency of KRAS mutations should be high, especially in patients with emphysema and a history of smoking. Therefore, testing for KRAS mutation may be more appropriate than testing for EGFR mutation in such patients. Once a KRAS mutation has been confirmed, at present, conventional cytotoxic chemotherapeutic agents are selected without further testing for driver mutations. However, since, in the absence of emphysematous changes, the frequency of EGFR mutation increases significantly (Odds Ratio=3.47, 95% confidence interval=1.5-8.2) even in patients with a history of smoking, testing for EGFR mutation and probably the ALK fusion gene is recommended. To establish this strategy for driver mutation testing, further studies should determine the frequency of KRAS and ALK fusion genes in smokers with lung adenocarcinoma in the presence and absence of emphysema.
Limitations. This study has some limitations. Firstly, only EGFR mutation status was examined owing to clinical and technical reasons. Evaluation of other genetic abnormalities including KRAS status and ALK fusion is needed to further confirm our speculation in terms of non-smoking-associated lung cancer in smokers. Secondly, we used visual scores to assess the presence and extent of emphysema, although quantitative standardized assessments with computer algorithms can also be used. The advantage of our study is that visual assessment does not require additional software and is simple, and previous studies have shown the validity of this approach (50) (51) (52) (53) .
Conclusion
In this study, EGFR mutations were frequently observed in the non-emphysema group, which is characterized by nonsmoking-associated lung cancer. Moreover, the absence of emphysema was independently associated with EGFR mutations. Consequently, the impact of smoking on lung carcinogenesis may differ according to the presence or absence of emphysema among smokers with lung cancer. 
